Roche's Enspryng Gets FDA Priority Review For MOGAD

Roche said the FDA granted priority review to its supplemental Biologics License Application for Enspryng in myelin oligodendrocyte glycoprotein antibody-associated disease. The expedited FDA review is a positive regulatory catalyst that could broaden Enspryng's approved indications, though approval and commercial potential remain uncertain.